These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31359813)

  • 1. Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study.
    Xing Y; Xie X; Xu J; Liu J; He Q; Yang W; Zhang N; Li X; Wang L; Fu J; Zhou J; Gao B; Ming J; Liu X; Lai J; Liu T; Shi M; Ji Q
    Expert Opin Drug Deliv; 2019 Sep; 16(9):995-1002. PubMed ID: 31359813
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of glucose variability in patients with type 2 diabetes administrated glargine with needle-free jet injector and conventional insulin pen.
    Sun Y; Wang J; Li H; Sun X; Su X; Ma J
    Expert Opin Drug Deliv; 2020 May; 17(5):713-717. PubMed ID: 32141347
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.
    Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB
    Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973
    [No Abstract]   [Full Text] [Related]  

  • 4. Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study).
    Ji L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    Adv Ther; 2019 Jun; 36(6):1485-1496. PubMed ID: 31004325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Kong X; Luo M; Cai L; Zhang P; Yan R; Hu Y; Li H; Ma J
    Expert Opin Drug Deliv; 2021 May; 18(5):635-641. PubMed ID: 33317342
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of needle-free injection on psychological insulin resistance and insulin dosage in patients with type 2 diabetes.
    Wang W; Men L; Wang Y; Shi C; Yin H; Li H; Zhou H; Du J
    Front Endocrinol (Lausanne); 2024; 15():1379830. PubMed ID: 38803476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.
    Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Horiuchi R; Utsunomiya K
    Diabetes Technol Ther; 2017 Aug; 19(8):457-462. PubMed ID: 28605286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical observation study on the effect of needle-free insulin syringe on blood glucose control and well-being index in patients with early-onset type 2 diabetes mellitus.
    Jin X; Sun Q; Yue C; Han J; Zhou X; Guan Q; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1137179. PubMed ID: 36864833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE study).
    Ji L; Gao L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    EClinicalMedicine; 2020 Jun; 23():100368. PubMed ID: 32529176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
    Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.
    Seufert J; Fritsche A; Pscherer S; Anderten H; Borck A; Pegelow K; Bramlage P; Pfohl M
    Diabetes Obes Metab; 2019 Feb; 21(2):439-443. PubMed ID: 30226296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.
    Hu X; Zhang L; Dong C; Dong Y; Jiang J; Gao W
    Adv Ther; 2019 May; 36(5):1132-1142. PubMed ID: 30900200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.